Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension.

作者信息

Trebicka Jonel, Schierwagen Robert

机构信息

Department of Internal Medicine I, University of Bonn, Bonn, Germany.

出版信息

Gut. 2015 Sep;64(9):1349-50. doi: 10.1136/gutjnl-2014-308800. Epub 2015 Jan 16.

DOI:10.1136/gutjnl-2014-308800

PMID:25596180

Abstract

摘要

相似文献

Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension.

Gut. 2015 Sep;64(9):1349-50. doi: 10.1136/gutjnl-2014-308800. Epub 2015 Jan 16.

Liver: Sussing out statins in cirrhosis--KLF2 is the key.

Nat Rev Gastroenterol Hepatol. 2015 Feb;12(2):64. doi: 10.1038/nrgastro.2014.233. Epub 2015 Jan 6.

KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins.

Gut. 2015 Sep;64(9):1434-43. doi: 10.1136/gutjnl-2014-308338. Epub 2014 Dec 10.

The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.

J Hepatol. 2013 Jan;58(1):98-103. doi: 10.1016/j.jhep.2012.08.026. Epub 2012 Sep 16.

Simvastatin suppresses the proangiogenic microenvironment of human hepatic stellate cells via the Kruppel-like factor 2 pathway.

Rev Esp Enferm Dig. 2015 Feb;107(2):63-71.

The effects of simvastatin-loaded nanoliposomes on human multilineage liver fibrosis microtissue.

J Cell Mol Med. 2024 Jul;28(13):e18529. doi: 10.1111/jcmm.18529.

Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.

Gut. 2017 Jan;66(1):145-155. doi: 10.1136/gutjnl-2015-309600. Epub 2015 Sep 17.

MicroRNA-101 suppresses liver fibrosis by targeting the TGFβ signalling pathway.

J Pathol. 2014 Sep;234(1):46-59. doi: 10.1002/path.4373. Epub 2014 Jun 17.

MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression.

Nat Commun. 2016 Mar 22;7:10993. doi: 10.1038/ncomms10993.

Effect of Kruppel-like factor 4 on Notch pathway in hepatic stellate cells.

J Huazhong Univ Sci Technolog Med Sci. 2016 Dec;36(6):811-816. doi: 10.1007/s11596-016-1667-7. Epub 2016 Dec 7.

引用本文的文献

Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension.

Front Med (Lausanne). 2025 Jan 31;12:1515400. doi: 10.3389/fmed.2025.1515400. eCollection 2025.

The effects of simvastatin-loaded nanoliposomes on human multilineage liver fibrosis microtissue.

J Cell Mol Med. 2024 Jul;28(13):e18529. doi: 10.1111/jcmm.18529.

Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells.

Pharmaceutics. 2023 Oct 14;15(10):2463. doi: 10.3390/pharmaceutics15102463.

Statin Use in Patients With Chronic Liver Disease and Cirrhosis: Current Evidence and Future Directions.

Gastroenterology Res. 2022 Feb;15(1):1-12. doi: 10.14740/gr1498. Epub 2022 Feb 25.

Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.

J Hepatol. 2022 May;76(5):1100-1108. doi: 10.1016/j.jhep.2021.12.034. Epub 2022 Jan 21.

Exogenous extracellular matrix proteins decrease cardiac fibroblast activation in stiffening microenvironment through CAPG.

J Mol Cell Cardiol. 2021 Oct;159:105-119. doi: 10.1016/j.yjmcc.2021.06.001. Epub 2021 Jun 10.

Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH.

Dis Model Mech. 2021 May 1;14(5). doi: 10.1242/dmm.048884. Epub 2021 May 20.

Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes.

Dig Dis Sci. 2022 Apr;67(4):1379-1388. doi: 10.1007/s10620-021-06955-x. Epub 2021 Mar 29.

Statins for treatment of chronic liver disease.

Curr Opin Gastroenterol. 2021 May 1;37(3):200-207. doi: 10.1097/MOG.0000000000000716.

Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves' Ophthalmopathy-Derived Orbital Fibroblasts RhoA-Mediated ERK and p38 Signaling Pathways.

Front Endocrinol (Lausanne). 2021 Feb 1;11:607968. doi: 10.3389/fendo.2020.607968. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr
超能文献

Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr超能文献

Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Suppr
超能文献